JAVELIN膀胱100研究患者报告结局:阿维鲁单抗一线维持联合最佳支持治疗对比单用最佳支持治疗晚期尿路上皮癌
JAVELIN膀胱100随机3期试验纳入700例一线含铂化疗后未进展的局部晚期或转移性尿路上皮癌患者,评估阿维鲁单抗联合最佳支持治疗对比单用最佳支持治疗的患者报告结局。两组FBlSI-18和EQ-5D-5L描述性分析及混合效应模型结果相似,预设分析至恶化时间风险比1.26(95%CI 0.90-1.77)。结论为阿维鲁单抗一线维持联合最佳支持治疗延长总生存且对生活质量影响相对较小。
要点
- 阿维鲁单抗维持联合最佳支持治疗对比单用最佳支持治疗,患者报告结局量表评分两组相似。
- 预设至恶化时间分析风险比1.26(95%CI 0.90-1.77),两组至恶化时间相似。
- 阿维鲁单抗一线维持联合最佳支持治疗延长总生存,对生活质量影响相对较小。
核心结论
- 在含铂一线化疗后未进展的晚期尿路上皮癌患者中,阿维鲁单抗一线维持联合最佳支持治疗对比单用最佳支持治疗延长总生存,同时对生活质量影响相对较小。
研究设计与样本
- 随机3期试验(NCT02603432),纳入700例一线吉西他滨联合顺铂或卡铂后未进展的局部晚期或转移性尿路上皮癌患者。
- 患者随机接受阿维鲁单抗联合最佳支持治疗(n=350)或单用最佳支持治疗(n=350),患者报告结局为次要终点。
- 采用FBlSI-18和EQ-5D-5L量表评估,使用描述性统计和混合效应模型分析。
主要发现
- 按计划治疗期间患者报告结局评估完成率>90%(总体及每次评估平均值)。
- FBlSI-18和EQ-5D-5L的描述性分析及混合效应或重复测量模型结果两组相似。
- 预设至恶化时间分析风险比1.26(95%CI 0.90-1.77),两组至恶化时间相似。
- 事后分析纳入治疗外评估及不同事件定义时,至恶化时间亦相似。
关键数值与推荐
- 至恶化时间预设定义:FBlSI-18疾病相关症状-躯体亚量表较基线下降≥3分且连续两次评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 开放性设计。
- 后期时间点可评估患者数量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In JAVELIN Bladder 100, avelumab first-line maintenance plus best supportive care (BSC) significantly prolonged overall survival (OS; primary endpoint) versus BSC alone in patients with advanced urothelial carcinoma (aUC) without disease progression with first-line platinum-containing chemotherapy. OBJECTIVE: To evaluate patient-reported outcomes (PROs) with avelumab plus BSC versus BSC alone. DESIGN, SETTING, AND PARTICIPANTS: A randomized phase 3 trial (NCT02603432) was conducted in 700 patients with locally advanced or metastatic urothelial carcinoma that had not progressed with first-line gemcitabine plus cisplatin or carboplatin. PROs were a secondary endpoint. INTERVENTION: Avelumab plus BSC (n = 350) or BSC alone (n = 350). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBlSI-18) and EuroQol five-level EQ-5D (EQ-5D-5L) assessments were analyzed using descriptive statistics and mixed-effect models. Time to deterioration (TTD; prespecified definition: a ≥3-point decrease from baseline in the FBlSI-18 disease-related symptoms-physical subscale for two consecutive assessments) was evaluated via Kaplan-Meier analyses. RESULTS AND LIMITATIONS: Completion rates for scheduled on-treatment PRO assessments were >90% (overall and average per assessment). Results from descriptive analyses and mixed-effect or repeated-measures models of FBlSI-18 and EQ-5D-5L were similar between arms. TTD was also similar, both in the prespecified analysis (hazard ratio 1.26 [95% confidence interval: 0.90, 1.77]) and in the post hoc analyses including off-treatment assessments and different event definitions. Limitations included the open-label design and limited numbers of evaluable patients at later time points. CONCLUSIONS: Addition of avelumab first-line maintenance to BSC in patients with aUC that had not progressed with first-line platinum-containing chemotherapy prolonged OS, with a relatively minimal effect on quality of life. PATIENT SUMMARY: In this trial of people with advanced urothelial carcinoma who had benefited from first-line chemotherapy (ie, had stable disease or reduced tumor size), treatment with avelumab maintenance plus best supportive care (BSC) versus BSC alone improved survival significantly, without compromising quality of life, as reported by the patients themselves.
引用
- Grivas P, Kopyltsov E, Su PJ, et al. Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma. Eur Urol. 2022. PMID: 35654659. doi:10.1016/j.eururo.2022.04.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。